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Abstract
Background: The global spread of carbapenem resistant Enterobacteriaceae 
(CRE) has limited the physicians’ antimicrobial treatment options of infected pa-
tients. CREs’ which carry the Klebsiella pneumonia Carbapenemase (blaKPC) resis-
tance mechanism have been rapidly spreading in many parts of the world, and 
have been responsible for high patients’ morbidity and mortality. 
Methods: Two protocols recommended by the Centers for Disease Control and 
Prevention (CDC) were followed to detect CREs’ in Palestine. In addition, the anti-
microbial sensitivity patterns for several antibiotic classes were determined for the 
isolated CREs’ by the disc diffusion method according to the clinical and laboratory 
standard institute (CLSI) M100-S22 guidelines. The Minimal Inhibitory Concentra-
tions (MICs) of the carbapenem, ertapenem, imipenem and meropenem were 
determined for all the CREs’ by E-test. The isolates β-lactam resistance mechanisms 
were further investigated by analyzing 31 different types of β–lactamase genes by 
polymerase chain reaction (PCR).
Results: Four bacterial isolates, three Enterobacter cloacae and one Klebsiella 
pneumoniae, were determined to be non-susceptible to one or all of the carbapen-
ems (ertapenem, imipenem and meropenem) tested. All isolates which carried the 
blaKPC-2 gene showed an extreme drug resistance profile. These isolates were re-
sistant to all β-lactam antibiotics, co-trimoxazole and gentamicin, while susceptible 
to only amikacin and colistin sulfate. Different combination of plasmid encoded 
β–lactamase genes (blaTEM, blaSHV, blaOXA-1, blaMIR-1, blaGES-23 and blaKPC-2) were 
present in these isolates. Of interest, was the isolation of the first E. cloacae strains 
co-producing the blaKPC-2 and a novel blaGES-23 β-lactamase.
Conclusions: The presence of all these plasmid encoded β-lactamase in Palestine 
is alarming and mandates actions to be taken to control antibiotics usage and the 
activation of hospital infection control programs in order to prevent the spread of 
these extremely drug resistant bacteria.
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Introduction
The emergence of carbapenem resistant Enterobacteriaceae 
(CRE) has complicated the management of infected or col-
onized patients (1). Carbapenems are usually the last class 
of antibiotics used to treat infections caused by resistant 
bacteria such as the ones carrying the Extended Spectrum 
β-Lactamases (ESBLs’). Since the description of the class A 
serine β-lactamases (blaNMC, blaIMI, blaSME, blaGES and blaK-
PC), which are mainly encoded on plasmids, Klebsiella pneu-
moniae carbapenemase (blaKPC) has been the only resistance 
mechanism to rapidly disseminate in many parts of the world.
The resistance mechanism, blaKPC, was first reported in a 
K. pneumoniae isolate detected in a patient residing in the 
United States of America (USA) in the year 2001 (2). Since 
then, bacterial isolates carrying this resistance mechanism 
have rapidly disseminated worldwide (1, 2). This in part could 
be due to the presence of the blaKPC genes on plasmids with 
varying sizes and structures (3). Bacterial isolates carrying the 
blaKPC resistance mechanism have been reported in several 
countries such as the USA, Switzerland, China, Israel, Canada, 
France, Colombia, Greece, Brazil and Italy (4-13). Indeed, sev-
eral countries became “Hot Spots” for such bacterial drug 
resistance mechanism. These countries include the eastern 
part of the USA, Israel, Greece and the eastern part of China 
(1). Interestingly, reports about the isolation of blaKPC prodcu-
ing members of the Enterobacteriaceae family in the Arabic 
speaking Middle Eastern countries were scarce.
Reports from varying parts of the world have shown that 
bacteria carrying the blaKPC gene are usually non-suscepti-
ble to co-trimoxazole, fluoroquinolones and the aminogly-
cosides, while the majority of the isolates are susceptible to 
tigecycline and colistin sulfate (1, 4, 12). The variation in sus-
ceptibility patterns and the heterogeneous expression of the 
β-lactamases, have complicated the detection of the blaKPC 
resistance mechanism in the clinical laboratory (14, 15). In-
deed, automated systems have been reported to miss the 
detection of blaKPC resistance mechanism in 7% to 87% of 
the blaKPC positive K. pneumoniae (15). Not only that, but 
the utilization of the imipenem and meropenem antibiotics in 
the disk diffusion assays has also been shown to misidentify 
carbapenem resistance due to blaKPC in 29% and 52% of the 
cases, respectively (16). On the other hand, the utilization of 
the carbapenem; ertapenem, has been shown to consistently 
identify blaKPC resistance mechanism. Nevertheless, within 
the Enterobacteriaceae family, not all ertapenem resistance 
is due to blaKPC (17).
The inconsistency in the performance of standardized clas-
sical microbiology assays has led to the utilization of mo-
lecular assays for the rapid detection and identification of 
the carbapenem resistant bacteria. Several highly sensitive 
Polymerase Chain Reaction (PCR) assays and Real-Time PCR 
assays have been developed and validated for the rapid de-
tection and identification of blaKPC positive bacteria (18-21). 
However, one of the disadvantages of these assays was the 
need for specialized equipment and well trained personnel. 
Consequently, screening agar plates have been developed 
and utilized for the rapid detection of blaKPC resistant bac-
teria. Chromogenic agar, CHROMagarTM KPC (CHROMagar, 
France), has been evaluated for the detection of blaKPC posi-
tive bacteria. However, this agar base medium still missed 
certain strains of blaKPC positive Enterobacteracae (1, 22). 
More recently, the Drigalski agar-based culture medium was 
reported to have excellent sensitivity and specificity for the 
detection of bacteria carrying the blaKPC resistance mecha-
nism (1).
In this study, we report the emergence and characterization 
of blaKPC positive bacteria in Palestine. Antimicrobial suscep-
tibility testing and β-lactamase antimicrobial resistance gene 
families were also investigated. 
Materials and Methods
Patient surveillance samples
Caritas Baby Hospital (CBH) is an 89 bed pediatric hospital 
located in the district of Bethlehem, Palestine. As a result 
of the increase in the dissemination of Methicillin-resistant 
Staphylococcus aureus (MRSA), Vancomycin Resistant Entero-
coccus (VRE), multi-drug resistant Acinetobacter baumannii 
and carbapenem resistant Enterobacteriaceae (CRE), in partic-
ular the blaKPC resistance mechanism, CBH infection control 
unit mandates that all patients referred to CBH from other 
medical institutions should undergo surveillance for drug re-
sistant bacteria. Since 2008, rectal, nose and umbilical swabs 
(N = 5,928) were collected on Copan Amies sterile transport 
swabs (Copan Diagnostics, Corona, CA) by the nursing staff 
members from all patients upon admission to the hospital 
sections. All swabs were transported to the clinical laboratory 
within 30 minutes for analysis.
Detection of carbapenem resistant 
Enterobacteriaceae 
Two different protocols were utilized to detect CREs’ as re-
ported by the American Centers for Disease Control and Pre-
vention (CDC) (23).
Protocol one: surveillance swabs received by the laboratory 
personnel were inoculated on MacConkey agar plates (Oxoid, 
United Kingdom), ensuring that all sides of the swab touched 
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the initial quadrant. The initial quadrant was plated as a lawn, 
and a meropenem (10μg) and an ertapenem (10μg) disks 
were placed in this area using sterile forceps. After overnight 
incubation at 37oC, inoculated MacConkey agar plates were 
evaluated for the presence of colonies within the inhibition 
zone of the meropenem and ertapenem disks. 
Protocol two: the same surveillance swabs used in protocol 
one were inoculated in 5ml trypticase soy broth (TSB) (Oxoid, 
United Kingdom) after a 10µg meropenem disk was placed 
into the broth using a sterile forceps. After overnight incuba-
tion at 37oC, the inoculated tube was vortexed for 15 seconds 
and a 100µl aliquot was streaked on MacConkey agar plate 
and incubated overnight at 37oC in ambient air. All bacterial 
colonies were identified and sensitivity testing was performed 
as described below (24, 25).
Bacterial identification and antimicrobial 
susceptibility testing
All bacterial isolates suspected of being CREs’ were identified 
by the API-20E (bioMerieux, Inc., France) according to the 
manufacturer’s instructions. Susceptibility testing was per-
formed by disk diffusion method on Mueller Hinton agar as 
recommended by the Clinical and Laboratory Standard Insti-
tute guidelines (CLSI) (25). Susceptibility patterns were deter-
mined for amikacin (30µg), amoxycillin/clavulanate (20/10µg 
), aztreonam (30µg), chloramphenicol (30µg), ceftazidime 
(30µg), ceftazidime/clavulanate (30/10 µg), ciprofloxacin 
(5µg), gentamicin (10µg), cefpodoxime (10µg), ceftriaxone 
(30 µg), cefotaxime (30µg), cefotaxime/ clavulanate (30/10 
µg), ertapenem (10µg), nitrofurantoin (300µg), cefepime 
(30µg), cefoxitin (30µg), imipenem (10µg), meropenem 
(10µg), norfloxacin (10µg), ofloxacin (5µg), co-trimoxazole 
(23.75/1.75 µg), tigecycline (15µg), piperacillin/tazobactam 
(100/10 µg), colistin sulfate (10 µg) (Oxoid, UK). All bacterial 
isolates that exhibited an intermediate or resistant profile to 
any of the carbapenems tested (ertapenem, imipenem and 
meropenem) were further evaluated by the modified Hodge 
test (25). In addition, carbapenems resistance was confirmed 
by determining the Minimal Inhibitory Concentration (MIC) 
of ertapenem, imipenem and meropenem using the Etest® 
(bioMe´rieux Inc.) on Mueller-Hinton plates (Oxoid, United 
Kingdom).
Polymerase Chain Reaction (PCR) Amplification of 
Different β-Lactamase Genes
Analysis of the β-lactamase gene groups, Extended Spectrum 
β-Lactamase (ESBL) [blaTEM, blaSHV, blaCTX-M-2 and -5, blaCTX-
M, blaOXA-1, blaOXA-2 and -20, blaOXA-5 and -10, blaPER-1 and 
-2],and blaAmpC (blaACT-1, blaMIR-1, blaCMY, blaLAT, blaFOX-1 to 
5, blaACC-1, blaDHA-1 and -2), in addition to the different carbap-
enem resistance molecular classes (class A: blaKPC, blaNMC-A, 
blaSME, blaGES; class B: blaNDM, blaIMP, blaVIM, blaGIM, blaSPM, 
blaSIM; class D: blaOXA-69, blaOXA-60, blaOXA-55, blaOXA-48, 
blaOXA-50) were performed as previously reported (18, 26, 
27). Briefly, suspected bacterial isolates were streaked for 
isolation on 5% Sheep Blood agar (SBA) (Hy-labs, Rehovot) 
and incubated at 35oC for 18-24 hours. Well isolated colo-
nies were used to prepare 2.0 MacFarland standard in sterile 
saline, of which, 100ml aliquot was heated at 100oC for 15 
minutes to prepare the bacterial cell lysates that were used 
for the PCR analysis. PCR amplification was performed in MJ-
P-100 Thermocycler using the recommended amplification 
conditions (18, 26). The primers used to determine the type 
of the amplified blaKPC PCR product were: forward 5’-atgt-
cactgtatcgccgtct-‘3 and reverse 5’-ttttcagagccttactgccc-‘3. In 
addition, the primers used to determine the type of the am-
plified blaGES gene were: forward 5’-atgcgcttcattcacgcac-‘3 
and reverse 5’-ctatttgtccgtgctcagga -‘3. The amplified PCR 
products were visualized on 1.0% agarose gel (Life Technolo-
gies, USA) after staining with ethidium bromide.
Determining blaKPC and blaGES types by sequence 
analysis
Amplified PCR products of the expected size for blaKPC 
(882bp) and blaGES (864bp) were purified using HighPure PCR 
product Purification Kit (Roche, Germany) and sequenced us-
ing the BigDye® Terminator V1.1 Sequencing Standard Kit 
(Life Technologies, USA). Sequence analysis was performed 
on the Applied Biosystems 3130 Genetic Analyzer (Life Tech-
nologies, USA) and analyzed using the Sequencher 5.0 (Gene 
Code Corporation, USA). The obtained nucleotide sequences 
were compared with previously described blaKPC and blaGES 
sequences obtained from the GenBank database (http://
www.lahey.org/Studies/other.asp).
Results
Detection of carbapenem resistant 
Enterobacteriaceae (CRE)
Four different bacterial strains (3 Enterobacter cloacae and 1 
Klebsiella pneumoniae) were isolated from the rectal swabs 
of 2 patients upon referral to CBH from local and regional 
medical institutions (Table 1). The 3 E. cloacae strains were 
isolated from a patient with prior hospitalization in an Israeli 
medical institution while the patient with the K. pneumoniae 
had prior hospitalization in a Palestinian medical institution. 
All isolates were detected by both protocols used to isolate 
CRE. The modified Hodge Test confirmed the presence of the 
carbapenemase enzyme as all four isolates produced a clear 
clover leaf-type indentation (Figure 1).
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tivity patterns were observed for the fluoroquinolones. All 
isolates had a non-susceptible antibiotic profile for ciprofloxa-
cin, while depending on the isolate; a susceptible and non-
susceptible profile was noted for norfloxacin and ofloxacin 
(Table 2). Similarly, a variable sensitivity pattern was noted 
for the bacteriostatic antibiotic tigecycline. Complete sensitiv-
ity patterns were noted only for amikacin and colistin sulfate. 
PCR amplification of β-lactamase genes and 
sequence analysis of blaKPC and blaGES PCR 
products
PCR amplification of 31 different β-lactamase genes repre-
senting members of the ESBL’s, AmpC, and the carbapen-
emases revealed that carbapenem resistance in the 4 isolates 
was due to the presence of the blaKPC carbapenemase (Table 
3). In addition, the three E. cloacae isolates also co-produced 
the Guiana extended-spectrum β-lactamases (blaGES) (Table 
3). Sequence analysis of the blaKPC (760 base pair) and blaGES 
(823 base pairs) PCR products revealed that all 4 bacterial 
isolates carried the blaKPC-2 gene while the 3 E. cloacae iso-
lates co-produced a novel type of the blaGES called blaGES-23 
gene. The blaGES-23 had a point silent mutation at nucleotide 
position 159 where the nucleotide cytosine was replaced by 
an adenine in all three E. cloacae. All 3 blaGES-23 sequences 
were deposited in the Genbank under the accession numbers 
JX437086-88. With regard to the ESBL genes, all isolates car-
ried the blaTEM and blaSHV genes, while none carried any of 
the blaCTX genes. Moreover, three of the isolates (2 E. cloacae 
and 1 K. pneumoniae) carried the blaOXA-1 gene (Table 3). 
As for the blaAmpC β-lactamases, the blaMIR-1 gene was 
detected in the 3 E. cloacae while it was absent in the K. 
pneumoniae isolate (Table 3).
Discussion
The emergence of carbapenem resistant Enterobacteriaceae 
(CRE) has exerted an unprecedented pressure on the health 
Table 1. Description of the carbapenemase positive bacterial isolates.
Bacterial  
Isolate
Isolate 
Number
Sample 
Collection Site
Patient 
Sex / Age
Date of 
Detection
Referral 
Hospital
Patients 
Residency
E. cloacae 1A1 Rectal F/ 2 months February 2008 Israeli Hebron
E. cloacae 1A2 Rectal F/ 2 months February 2008 Israeli Hebron
E. cloacae 1A3 Rectal F/ 2 months February 2008 Israeli Hebron
K. pneumoniae 1A4 Rectal F/ 6 months March 2012 Palestinian Ramallah
Figure 1:  Modified Hodge Test of the four blaKPC positive iso-
lates (1A1, 1A2, 1A3 and 1A4) and an E. coli (ESBL 
producer) as a negative control. All four blaKPC posi-
tive isolates produced the characteristic cloverleaf-like 
indentation, while the negative control, E. coli (ESBL), 
positive did not produce the characteristic indentation.
Antimicrobial susceptibility patterns
Antimicrobial susceptibility testing of the CRE isolates for 24 
different antibiotics revealed a multi-drug resistant profile 
(Table 2). Non-susceptible antibiotic profile was noted to all 
of the β–lactam antibiotics, co-trimoxazole and gentamicin. 
Determination of the MIC of the carbapenems (ertapenem, 
imipenem and meropenem) by Etest®, confirmed the resis-
tance profile to the carbapenems. All isolates had carbapen-
ems MIC’s greater than 32 µg/ml (Table 2). Variable sensi-
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care provider’s ability to manage infected or colonized pa-
tients. This in part was due to the limited antimicrobial op-
tions available for treating infected patients and to the recom-
mendations for isolating patients with CRE. Of interest was 
the rapid dissemination of blaKPC resistant bacteria in the 
Eastern part of the USA, China, Greece and Israel (4, 10, 12, 
17, 28). Other countries in the world have reported sporadic 
isolation of Enterobacteriaceae family members carrying the 
blaKPC resistance mechanism (1). However, reports about the 
isolation of blaKPC producing members of the Enterobacte-
riaceae family in any of the Arabic Middle Eastern countries 
are infrequent.
Antibiotic 
(concentration)
1A1 1A2 1A3 1A4
E. cloacae
DD / E-Test
E. cloacae
DD / E-Test
E. cloacae
DD / E-Test
K. pneumoniae
DD / E-Test
Amikacin (30µg) S S S S
Gentamicin (10µg) R R R R
Amoxycillin / 
Clavulanate (20/10µg ) R R R R
Piperacillin / Tazobactam 
(100/10µg) R R R R
Aztreonam (30µg) R R R R
Ceftazidime (30µg) R R R R
Ceftazidime / 
Clavulanate (30/10µg) R R R R
Cefotaxime (30µg) R R R R
Cefotaxime / 
Clavulanate (30/10µg) R R R R
Cefpodoxime (10µg) R R R R
Ceftriaxone (30µg) R R R R
Cefepime (30µg) R R R R
Cefoxitin (30µg) R R R I
Ofloxacin (5µg) I I S S
Ciprofloxacin (5µg) R R R I
Norfloxacin (10µg) R I I S
Nitrofurantoin (300µg) S S S I
Chloramphenicol (30µg) R R R S
Co-trimoxazole 
(23.75/1.75µg) R R R R
Ertapenem (10µg) R / >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml
Imipenem (10µg) R / >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml
Meropenem (10µg) R / >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml R/ >32 µg/ml
Tigecycline (15µg) I I I S
Colistin sulfate (10µg) S S S S
Table 2.  Antimicrobial susceptibility patterns of the different blaKPC positive isolates was determined and interpreted by 
the disk diffusion (DD) method, while the MIC’s for the carbapenems (ertapenem, imipenem and meropenem) 
were determined by the E-test. The interpretation of the sensitivity patterns were: S = Sensitive; I = Intermediate; 
R = Resistant.
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Because of medical tourism, a large number of Palestinians 
living in occupied Palestine seeks the medical services in the 
Israeli hospitals. Since blaKPC positive Enterobacteriaceae has 
disseminated in the majority of Israeli medical institutions, 
Palestinians who were hospitalized in Israel and are return-
ing back to the Palestinian hospitals have a high probability 
of being colonized with blaKPC positive Enterobacteriaceae 
(10, 20). Indeed, this report describes the first isolation of 
blaKPC positive E. cloacae isolated from a patient upon ad-
mission to Caritas Baby Hospital right after hospitalization in 
an Israeli hospital. In addition, what was more alarming was 
the detection of blaKPC positive K. pneumoniae in a patient 
Table 3. Determination of the presence of several β-lactamase genes in the carbapenem resistant isolates by PCR.
Group β-lactamase Genes
1A1 1A2 1A3 1A4
E. cloacae E. cloacae E. cloacae K. pneumoniae
ESBL
blaTEM Positive Positive Positive Positive
blaSHV Positive Positive Positive Positive
blaCTX-M-2 and 5 Negative Negative Negative Negative
blaCTX-M Negative Negative Negative Negative
blaOXA-1 Negative Positive Positive Positive
blaOXA-2 and 20 Negative Negative Negative Negative
blaOXA-5 and 10 Negative Negative Negative Negative
blaPER-1 and 2 Negative Negative Negative Negative
blaAmpC
blaACT-1 Negative Negative Negative Negative
blaMIR-1 Positive Positive Positive Negative
blaCMY and LAT Negative Negative Negative Negative
blaFOX-1 and 5 Negative Negative Negative Negative
blaDHA-1 and 2 Negative Negative Negative Negative
blaACC-1 and 2 Negative Negative Negative Negative
Class A
blaKPC Positive Positive Positive Positive
blaNMC Negative Negative Negative Negative
blaSME Negative Negative Negative Negative
blaGES Positive Positive Positive Negative
Class D
blaOXA-69 Negative Negative Negative Negative
blaOXA-55 Negative Negative Negative Negative
blaOXA-48 Negative Negative Negative Negative
blaOXA-50 Negative Negative Negative Negative
blaOXA-60 Negative Negative Negative Negative
Class B
blaIMP-1 Negative Negative Negative Negative
blaIMP-2 Negative Negative Negative Negative
blaVIM-1 Negative Negative Negative Negative
blaVIM-2 Negative Negative Negative Negative
blaSPM-1 Negative Negative Negative Negative
blaGIM-1 Negative Negative Negative Negative
blaSIM-1 Negative Negative Negative Negative
blaNDM Negative Negative Negative Negative
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with no prior travel history outside occupied Palestine. Thus, 
indicating the emergence of this resistance mechanism in the 
Palestinian hospitals.
Consistent with earlier reports that blaKPC positive Enterobac-
teriaceae are usually multidrug resistant organisms, all isolates 
reported here showed multidrug resistance profile (12, 17, 
29). Indeed, all isolates were resistant to all β–lactam anti-
biotics, co-trimoxazole, and gentamicin. High carbapenems 
(ertapenem, imipenem and meropenem) with MIC’s (>32mg/
mL) confirmed the disk diffusion results, while the presence 
of carbapenemase enzymes was confirmed by the modified 
Hodge test. Variable sensitivity patterns were noted for the 
fluoroquinolones (ofloxacin, ciprofloxacin and norfloxacin), 
tigecycline, and nitrofurantoin which further complicate pa-
tient’s infection management. Complete susceptible patterns 
were noted only to amikacin and colistin sulfate, thus leaving 
the health care providers with limited options for how to treat 
patients infected with blaKPC positive bacteria (Table 2). E. 
cloacae and K. pneumoniae isolates positive for the blaKPC 
gene and with similar drug resistance profile as in occupied 
Palestine have been previously reported from several Israeli 
medical institutions and several countries worldwide (1, 10, 
30-37).
Eleven different types of blaKPC genes have been reported in 
different bacterial genuses worldwide, of which blaKPC-2 and 
blaKPC-3 are endemic in Israel (26). Sequence analysis of the 
four Palestinian bacterial blaKPC genes revealed that they all 
belong to blaKPC-2 type. BlaKPC-2 which has been reported 
in Israel and in several countries worldwide differ from the 
widely disseminated blaKPC-3 by only one amino acid differ-
ence at position 272, where histidine was replaced by tyrosine 
(H272Y) (35).
The extremely drug resistance profile that the Palestinian 
blaKPC-2 isolates exhibited was further investigated by screen-
ing the bacterial cell lysates for the presence of different β–
lactamase genes by PCR. Of the 31 different β–lactamase 
genes investigated, all isolated lysates contained the blaTEM 
and blaSHV genes. Several E. cloacae and K. pneumoniae iso-
lates carrying the β–lactamase genes; blaKPC-2, blaTEM and 
blaSHV have been previously reported from several countries 
(35, 38-40). On the other hand, the blaOXA-1 was detected 
in the E. cloacae isolates 1A2, 1A3 and the K. pneumoniae 
isolates 1A4, while the blaAmpC (blaMIR-1) was detected in 
all E. cloacae isolates 1A1, 1A2 and 1A3. The presence of 
these resistance mechanisms in combination with the blaKPC 
is extremely rare and at the same time alarming as these 
plasmids encoded β-lactamase genes, ESBL’s and blaAmpC, 
can easily spread from one bacteria to another in the hospital 
setting (41, 42). 
What was more disturbing was the detection of the plasmid 
encoded blaGES gene in the three E. cloacae isolates. The 
blaGES enzymes possess an unusual phenotypic plasticity, 
since they have activities against carbapenems, extended-
spectrum β-lactams, cephamycins and monobactams (43). 
The presence of the blaGES-23 enzyme which might have 
some carbapenemase activity with the blaKPC-2 is a strong 
reminder about the seriousness of this emerging problem. 
This is of extreme importance since it represents, to our 
knowledge, the first report of the presence of both blaKPC 
and blaGES genes in a member of the Enterobacteriaceae 
family. Indeed, the co-production of blaKPC and blaGES has 
been previously reported in an Aeromonas spp. isolated from 
hospital sewage in Brazil (44).
The presence of all these plasmids encoded β–lactamase (bla-
TEM, blaSHV, blaOXA-1, blaMIR-1, blaGES-23 and blaKPC-2) genes 
is the Palestinian bacterial isolates is alarming and mandates 
the Palestinian Ministry of Health (Pal-MOH) to take practical 
steps in order to help the Palestinian hospitals in detecting 
these extremely drug resistant pathogens. In addition, the 
Pal-MOH must take action in controlling the misuse of anti-
biotics and must mandate activation and monitoring of the 
Palestinian hospitals infection control programs in order to 
prevent the spread of these extremely drug resistant bacteria. 
In Palestine, the presence of these resistance mechanisms 
does not preclude the presence of other rapidly spreading 
carbapenemases in the Enterobacteriaceae family such as the 
recently reported blaOXA-48 in Lebanon (45).
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